Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 30;14:1251593. doi: 10.3389/fimmu.2023.1251593

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Gerbitz, Gary, Aigner, Moosmann, Kremer, Schmid, Hirschbuehl, Wagner, Hauptrock, Teschner, Roesler, Spriewald, Tischer, Moi, Balzer, Schaffer, Bausenwein, Wagner, Schmidt, Brestrich, Ullrich, Maas, Herold, Strobel, Zimmermann, Weisbach, Hansmann, Lammoglia-Cobo, Remberger, Stelljes, Ayuk, Zeiser and Mackensen

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Outcomes. Database was closed on Dec 31^st 2020 with a median follow up of 930 days. (A) Kaplan-Meier estimates of overall survival of patients in both groups. (B) Cumulative incidence of transplant related mortality during the entire observation period. (C) Cumulative incidence of Relapse. Cumulative incidence of acute GvHD (all grades, (D)) and grade II-IV (E) requiring treatment during the study observation period of 204 days. There was no statistically significant difference between the groups for all outcomes shown.